Science

Razelle Kurzrock: Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience

Razelle Kurzrock/froedtert.com

Jan 21, 2025, 15:31

Razelle Kurzrock: Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience

Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared an article by Young Kwang Chae on X:

“Nivo/ipi is active in BAC. Some responses last for years.”

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).

Authors: Young Kwang Chae, et al.

Razelle Kurzrock: Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience

Adenocarcinoma cancer clinical research CTLA fight against cancer Global fight against cancer OncoDaily Oncology Razelle Kurzrock Wisconsin Cancer Center Young Kwang Chae

Senator Edward Markley in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity